GlassScriptPhysician profile
Imad Hussain
NPI 1568648244
$21,499.97
in general payments reported to CMS, 2019-2025
26 companies · $2,210 in 2025
The $2,210 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,175 · 2020: $8,533 · 2021: $199 · 2022: $887 · 2023: $809 · 2024: $687 · 2025: $2,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,809 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,809.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,431.60 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console |
| Astrazeneca Pharmaceuticals LP | $8,262.11 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,829.22 | 2025 | |
| Abiomed | $499.86 | 2019-2024 | Impella |
| Impulse Dynamics (USA) INC. | $419.17 | 2021-2024 | Optimizer, Optimizer |
| Actelion Pharmaceuticals US, INC. | $111.87 | 2019-2023 | Opsumit, Uptravi |
| Amgen INC. | $106.17 | 2019-2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $98.60 | 2019-2022 | |
| Cvrx, INC. | $89.29 | 2024 | Barostim Neo System |
| Boston Scientific Corporation | $80.91 | 2019 | |
| Pfizer INC. | $79.61 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $71.01 | 2023-2024 | |
| Bridgebio Pharma, INC. | $63.48 | 2025 | Attruby |
| Scpharmaceuticals INC. | $62.11 | 2023-2024 | |
| Medtronic Vascular, INC. | $47.33 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $38.34 | 2021-2023 | Flexitouch Plus, Entre Plus |
| Takeda Pharmaceuticals U.S.A., INC. | $32.88 | 2025 | Livtencity |
| Lemaitre Vascular, INC. | $30.00 | 2025 | Artegraft Vascular Graft |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.29 | 2025 | Lifevest |
| Haemonetics Corporation | $23.60 | 2019 | |
| Astellas Pharma US INC | $22.06 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.47 | 2025 | Eliquis |
| Novo Nordisk INC | $18.45 | 2025 | Wegovy |
| Abbvie INC. | $15.44 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.60 | 2023 | Jardiance |
| United Therapeutics Corporation | $7.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imad Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.